For the quarter ending 2025-06-30.
| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Product revenue | 0 | - | - | - |
| Product cost of sales | 0 | - | - | - |
| Gross income | 0 | - | - | - |
| Stock based compensation expenses | 104,854 | 84,636 | 301,941 | 13,762 |
| Research and development expenses | 873,472 | 1,545,513 | 1,166,079.5 | 707,747 |
| Administrative expenses | 894,297 | 841,685 | 1,018,732.5 | 1,104,130 |
| Series g warrant issuance expenses | 0 | - | 242,376.25 | - |
| Series f-1 warrant issuance expenses | 0 | - | 511,924.75 | - |
| Gain (losses) on fair value of derivative liability | - | - | - | -356,000 |
| Loss from operations | -1,872,623 | -2,471,834 | -2,486,753 | -1,825,639 |
| Changeinfairvalueofmarketablesecurities | - | - | - | 4,746 |
| Unrealized gain on marketable securities | - | - | 167.75 | - |
| Gainlossonsalesofmarketablesecurities | - | - | - | 551 |
| (gain)/loss on sale of marketable securities | 0 | - | 244 | - |
| Interest and dividend income | 57,575 | 62,512 | 83,355 | 163,951 |
| Gain on sale of investments | - | 2,176 | - | - |
| Casualtygainloss | - | - | - | 100,000 |
| Change in fair value of derivatives liabilities | 19,000 | 1,284,000 | - | - |
| Change in fair value of warrant liabilities | 0 | - | 3,547,000 | 17,000 |
| Change in fair value of derivatives liabilities | - | - | -97,000 | - |
| Loss on issuance of series g convertible preferred stock | 0 | - | 1,277,250 | - |
| Loss on issuance of series f-1 convertible preferred stock | 0 | - | 934,250 | - |
| Casualty loss/(gain) | - | - | 2,326,338.75 | - |
| Unrealized loss on marketable securities | - | -1,597 | - | - |
| Change in fair value of marketable securities | -147 | - | - | - |
| Total other (income)/expense | 76,428 | 1,347,091 | -3,445,394.5 | -103,752 |
| Loss before income tax | -1,796,195 | -1,124,743 | -5,932,147.5 | -1,929,391 |
| Income tax benefit | 0 | - | 0 | - |
| Net loss | -1,796,195 | -1,124,743 | -5,932,147.5 | -1,929,391 |
| Preferred stock dividends | 976,369 | 813,496 | 1,136,746.5 | 751,052 |
| Net loss attributable to common stockholders | -2,772,564 | -1,938,239 | -7,068,894 | -2,680,443 |
| Basic loss per common share | -0.18 | -0.36 | -2.75 | -1.11 |
| Diluted loss per common share | -0.18 | -0.36 | -2.75 | -1.11 |
| Weighted average basic common stock outstanding | 15,698,856 | 5,349,662 | -1,126,894 | 2,415,089 |
| Weighted average diluted common stock outstanding | 15,698,856 | 5,349,662 | -1,126,894 | 2,415,089 |
TNF Pharmaceuticals, Inc. (TNFA)
TNF Pharmaceuticals, Inc. (TNFA)